Singapore - English - HSA (Health Sciences Authority)

astrazeneca singapore pte ltd - trastuzumab deruxtecan - infusion, solution concentrate - trastuzumab deruxtecan 100 mg/vial

Canada - English - Health Canada

samsung bioepis co., ltd - trastuzumab - powder for solution - 150mg - trastuzumab 150mg

Canada - English - Health Canada

samsung bioepis co., ltd - trastuzumab - powder for solution - 440mg - trastuzumab 440mg

Canada - English - Health Canada

amgen canada inc - trastuzumab - kit - 420mg - trastuzumab 420mg - antineoplastic agents

Canada - English - Health Canada

amgen canada inc - trastuzumab - powder for solution - 150mg - trastuzumab 150mg - antineoplastic agents

Canada - English - Health Canada

seagen inc. - tucatinib - tablet - 50mg - tucatinib 50mg - antineoplastic agents

Canada - English - Health Canada

seagen inc. - tucatinib - tablet - 150mg - tucatinib 150mg - antineoplastic agents

Canada - English - Health Canada

pfizer canada ulc - trastuzumab - powder for solution - 440mg - trastuzumab 440mg - antineoplastic agents

Canada - English - Health Canada

pfizer canada ulc - trastuzumab - powder for solution - 150mg - trastuzumab 150mg - antineoplastic agents

New Zealand - English - Medsafe (Medicines Safety Authority)

roche products (nz) ltd - trastuzumab emtansine 100mg (plus 6% vial overfill = trastuzumab emtansine 106mg) - powder for infusion - 100 mg - active: trastuzumab emtansine 100mg (plus 6% vial overfill = trastuzumab emtansine 106mg) excipient: polysorbate 20 sodium hydroxide succinic acid sucrose - kadcyla as a single agent, is indicated for the treatment of patients with her2-positive, metastatic breast cancer who previously received trastuzumab and a taxane, separately or in combination. patients should have either: received prior therapy for metastatic disease, or developed disease recurrence during or within six months of completing adjuvant therapy. kadcyla, as a single agent, is indicated for the adjuvant treatment of patients with her2-positive early breast cancer who have residual disease after pre-operative systemic treatment that included her2-targeted therapy.